PAVmed Inc. [NASDAQ: PAVM] price surged by 7.79 percent to reach at $0.37. The company report on May 26, 2021 that PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), announced that Lucid’s EsoCheck® Esophageal Cell Collection Device with Collect+Protect™ technology (“EsoCheck”) has received CE Mark certification.
EU-based Notified Body TÜV Rhineland LGA Products GMBH issued a CE Certificate, effective May 24, 2021, declaring that EsoCheck conforms to the essential requirements of Medical Device Directive 93/42/EEC. With CE Mark secured, EsoCheck may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland, and Lichtenstein), Switzerland, and, until July 1, 2023, the United Kingdom.
A sum of 2992033 shares traded at recent session while its average daily volume was at 3.73M shares. PAVmed Inc. shares reached a high of $5.16 and dropped to a low of $4.635 until finishing in the latest session at $5.12.
Guru’s Opinion on PAVmed Inc. [PAVM]:
Cantor Fitzgerald have made an estimate for PAVmed Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 30, 2021. While these analysts kept the previous recommendation, Ascendiant Capital Markets raised their target price to Buy. The new note on the price target was released on November 05, 2020, representing the official price target for PAVmed Inc. stock. Previously, the target price had yet another raise to $5, while Maxim Group analysts kept a Buy rating on PAVM stock.
The Average True Range (ATR) for PAVmed Inc. is set at 0.36 The Price to Book ratio for the last quarter was 8.00, with the Price to Cash per share for the same quarter was set at 0.58.
PAVM Stock Performance Analysis:
PAVmed Inc. [PAVM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.58. With this latest performance, PAVM shares gained by 9.87% in over the last four-week period, additionally plugging by 150.98% over the last 6 months – not to mention a rise of 146.15% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PAVM stock in for the last two-week period is set at 62.39, with the RSI for the last a single of trading hit 71.46, and the three-weeks RSI is set at 58.40 for PAVmed Inc. [PAVM]. The present Moving Average for the last 50 days of trading for this stock 4.64, while it was recorded at 4.75 for the last single week of trading, and 2.89 for the last 200 days.
Insight into PAVmed Inc. Fundamentals:
PAVmed Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.20 and a Current Ratio set at 15.20.
PAVM Stock EPS
With the latest financial reports released by the company, PAVmed Inc. posted -0.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.1/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -30.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PAVM.
PAVmed Inc. [PAVM] Insider Position Details
There are presently around $93 million, or 21.70% of PAVM stock, in the hands of institutional investors. The top three institutional holders of PAVM stocks are: BLACKROCK INC. with ownership of 4,354,014, which is approximately 135.578% of the company’s market cap and around 5.00% of the total institutional ownership; VANGUARD GROUP INC, holding 3,462,716 shares of the stock with an approximate value of $17.73 million in PAVM stocks shares; and FMR LLC, currently with $7.17 million in PAVM stock with ownership of nearly New of the company’s market capitalization.
71 institutional holders increased their position in PAVmed Inc. [NASDAQ:PAVM] by around 9,970,293 shares. Additionally, 20 investors decreased positions by around 771,945 shares, while 10 investors held positions by with 7,387,183 shares. The mentioned changes placed institutional holdings at 18,129,421 shares, according to the latest SEC report filing. PAVM stock had 35 new institutional investments in for a total of 4,374,717 shares, while 10 institutional investors sold positions of 212,478 shares during the same period.